{"entity":{"id":"yuhan","kind":"company","name":"Yuhan Corporation","aka":["Yuhan","유한양행"],"tldr":"Yuhan Corporation is a South Korea-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the immuno-oncology candidates YH32364, YH32367 and YH42946 in non-small-cell lung cancer and advanced solid tumours.","summary":"Yuhan Corporation is a South Korean pharmaceutical company founded in 1926 that makes prescription medicines, health supplements, household and animal health products. Its research pipeline includes the lung cancer drug lazertinib and immuno-oncology candidates such as YH32364 and YH32367. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06616766 (phase 1/2, A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK an...), NCT06975410 (phase 1/2, Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpr...) and NCT05523947 (phase 1/2, Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.yuhan.co.kr"},{"label":"ClinicalTrials.gov: trials led by Yuhan Corporation","url":"https://clinicaltrials.gov/search?lead=Yuhan%20Corporation"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06616766","nct06975410","nct05523947"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"https://www.yuhan.co.kr","ticker":"KRX:000100","founded":1926,"stage":"public","investors":[],"funding":[]},"route":"/companies/yuhan/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"trial":[{"id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/"},{"id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","route":"/trials/nct06975410/"},{"id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","route":"/trials/nct05523947/"}]}}